Cargando…
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
Phosphatase of regenerating liver 3 (PRL3) is a specific tumor antigen overexpressed in a broad range of adult cancer types. However, its physiological expression in pediatric embryonal and mesenchymal tumors and its association with clinical outcomes in children is unknown. We sought to profile the...
Autores principales: | Loh, Amos Hong Pheng, Thura, Min, Gupta, Abhishek, Tan, Sheng Hui, Kuan, Kelvin Kam Yew, Ang, Koon Hwee, Merchant, Khurshid, Chang, Kenneth Tou En, Yon, Hui Yi, Chen, Yong, Cheng, Mathew Hern Wang, Mahadev, Arjandas, Ng, Matthew Chau Hsien, Seng, Michaela Su-Fern, Iyer, Prasad, Chia, Pei Ling, Soh, Shui Yen, Zeng, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477756/ https://www.ncbi.nlm.nih.gov/pubmed/37674627 http://dx.doi.org/10.1016/j.omto.2023.08.006 |
Ejemplares similares
-
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019) -
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021) -
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
por: Chee, Cheng E., et al.
Publicado: (2023)